A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Eli Lilly and Company
Astellas Pharma Inc
National Cancer Institute, Naples
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.